Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Synlogic 10M share Spot Secondary priced at $3.00 » 06:37
04/16/21
04/16
06:37
04/16/21
06:37
SYBX

Synlogic

$3.18 /

-0.08 (-2.45%)

SVB Leerink acted as sole…

SVB Leerink acted as sole book running manager for the offering.

ShowHide Related Items >><<
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

  • 16
    Apr
SYBX Synlogic
$3.18 /

-0.08 (-2.45%)

Syndicate
Synlogic announces common stock offering, no amount given » 16:05
04/15/21
04/15
16:05
04/15/21
16:05
SYBX

Synlogic

$3.17 /

-0.09 (-2.76%)

Synlogic announced that…

Synlogic announced that it has commenced an underwritten public offering of its common stock. SVB Leerink is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

SYBX Synlogic
$3.17 /

-0.09 (-2.76%)

Hot Stocks
Synlogic presents data from Phase 1 study of SYNB1618 for treatment of PKU » 09:23
04/13/21
04/13
09:23
04/13/21
09:23
SYBX

Synlogic

$3.33 /

-0.01 (-0.30%)

Synlogic presented data…

Synlogic presented data from the Phase 1 study of SYNB1618 for the treatment of Phenylketonuria, or PKU, during the American College of Medical Genetics, or ACMG, annual meeting, being held virtually April 13-16. The poster presentation, "Randomized, Placebo-Controlled Study of Lyophilized Formulation of SYNB1618 in Healthy Adult Volunteers," was delivered by Marja Puurunen, Synlogic's Senior Medical Director. The presentation recording will be available throughout the duration of the conference. PKU is an inherited metabolic disease that manifests at birth and is marked by an inability to break down phenylalanine, an amino acid that is commonly found in many foods. YNB1618 is an oral investigational Synthetic Biotic medicine designed to break down phenylalanine in the GI tract as a potential treatment for patients with PKU. A solid oral lyophilized powder formulation was evaluated in a Phase 1 study in healthy volunteers. In this study, the safety, tolerability and pharmacodynamics of multiple doses of SYNB1618 were assessed. Findings reported include: the solid oral formulation of SYNB1618 was well tolerated and metabolically active in the human GI tract; SYNB1618 reduced the increase of plasma D5-Phe following an oral dose of the tracer in a dose-dependent manner in healthy volunteers; SYNB1618 demonstrated evidence of activity in the fasted state. These data support the further clinical development of this therapy for the treatment of PKU. SYNB1618 continues to advance in a proof of concept Phase 2 clinical trial in adults with PKU, SynPheny, with data expected in the second half of 2021.

ShowHide Related Items >><<
SYBX Synlogic
$3.33 /

-0.01 (-0.30%)

SYBX Synlogic
$3.33 /

-0.01 (-0.30%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.33 /

-0.01 (-0.30%)

SYBX Synlogic
$3.33 /

-0.01 (-0.30%)

Conference/Events
Needham to hold a virtual conference » 09:12
04/12/21
04/12
09:12
04/12/21
09:12
GRCL

Gracell

$13.52 /

-0.82 (-5.72%)

, LMAT

LeMaitre

$51.38 /

+0.82 (+1.62%)

, IONS

Ionis Pharmaceuticals

$42.32 /

-0.32 (-0.75%)

, TSHA

Taysha Gene Therapies

$21.35 /

+1.49 (+7.50%)

, ZEAL

Zealand Pharma

$33.60 /

+1.27 (+3.93%)

, CLSD

Clearside Biomedical

$2.66 /

+0.12 (+4.72%)

, MEIP

MEI Pharma

$3.43 /

+0.12 (+3.63%)

, PCVX

Vaxcyte

$20.27 /

-0.49 (-2.36%)

, EVLO

Evelo Biosciences

$10.03 /

+0.005 (+0.05%)

, IVC

Invacare

$8.23 /

-0.08 (-0.96%)

, BSGM

BioSig Technologies

$4.59 /

+0.12 (+2.68%)

, CYTK

Cytokinetics

$24.17 /

+0.01 (+0.04%)

, SYBX

Synlogic

$3.34 /

-0.02 (-0.60%)

, RNA

Avidity Biosciences

$22.12 /

-1.8 (-7.53%)

, CSTL

Castle Biosciences

$69.44 /

-1.2 (-1.70%)

, AGI

Alamos Gold

$8.37 /

+0.08 (+0.97%)

, CARA

Cara Therapeutics

$29.09 /

+1.645 (+5.99%)

, FIX

Comfort Systems USA

$79.11 /

+1.925 (+2.49%)

, ITRM

Iterum Therapeutics

$1.30 /

-0.305 (-19.00%)

, LTRN

Lantern Pharma

$17.05 /

-0.13 (-0.76%)

, OCGN

Ocugen

$6.96 /

+0.045 (+0.65%)

, QURE

uniQure

$33.77 /

-1.75 (-4.93%)

, STTK

Shattuck Labs

$28.31 /

+1.365 (+5.07%)

, VKTX

Viking Therapeutics

$5.93 /

-0.23 (-3.73%)

20th Annual Virtual…

20th Annual Virtual Healthcare Virtual Conference will be held on April 12-15.

ShowHide Related Items >><<
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

02/03/21 Citi
Gracell initiated with a Buy at Citi
02/02/21 Jefferies
Gracell initiated with a Buy at Jefferies
02/02/21 Wells Fargo
Gracell initiated with an Overweight at Wells Fargo
02/02/21 Piper Sandler
Gracell initiated with an Overweight at Piper Sandler
LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

02/26/21 Barrington
LeMaitre price target raised to $49 from $47 at Barrington
02/12/21
Fly Intel: Top five analyst initiations
02/12/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
02/11/21 KeyBanc
LeMaitre initiated with a Sector Weight at KeyBanc
IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/23/21 Truist
Truist sees mixed readthroughs to Wave's toplines from competitor HD setback
03/23/21 BMO Capital
Ionis Pharmaceuticals price target lowered to $76 from $90 at BMO Capital
TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
02/23/21 William Blair
Taysha Gene Therapies initiated with an Outperform at William Blair
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

10/12/20 Brookline
MEI Pharma initiated with a Buy at Brookline
09/22/20 Alliance Global Partners
MEI Pharma initiated with a Buy at Alliance Global Partners
07/06/20 Truist
MEI Pharma price target lowered to $12 from $16 at SunTrust
05/29/20
Fly Intel: Top five analyst initiations
PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

07/16/20 Wells Fargo
Sutro Biopharma initiated with an Overweight at Wells Fargo
07/07/20
Fly Intel: Top five analyst initiations
07/07/20 BofA
Vaxcyte initiated with a Buy at BofA
07/07/20 Jefferies
Vaxcyte initiated with a Buy at Jefferies
EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

04/12/21 Jefferies
Jefferies upgrades Evelo Biosciences to Buy on increased microbiome momentum
04/12/21 Jefferies
Evelo Biosciences upgraded to Buy from Hold at Jefferies
03/12/21 Chardan
Evelo Biosciences price target raised to $15 from $10 at Chardan
01/25/21 JMP Securities
Evelo Biosciences price target raised to $36 from $27 at JMP Securities
IVC Invacare
$8.23 /

-0.08 (-0.96%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 SVB Leerink
Avidity Biosciences initiated with an Outperform at SVB Leerink
07/07/20 Cowen
Avidity Biosciences initiated with an Outperform at Cowen
07/07/20 Wells Fargo
Avidity Biosciences initiated with an Overweight at Wells Fargo
CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

03/09/21 Baird
Castle Biosciences price target lowered to $82 from $87 at Baird
02/03/21 KeyBanc
Castle Biosciences price target raised to $90 from $70 at KeyBanc
01/26/21 Canaccord
Castle Biosciences price target raised to $84 from $80 at Canaccord
01/15/21 SVB Leerink
Castle Biosciences price target raised to $80 from $70 at SVB Leerink
AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

02/10/21 JPMorgan
Alamos Gold initiated with a Neutral at JPMorgan
02/08/21 CIBC
Alamos Gold price target lowered to C$16 from C$19.25 at CIBC
02/02/21 National Bank
Alamos Gold price target lowered to C$14.50 from C$15.50 at National Bank
01/11/21 National Bank
Alamos Gold price target lowered to C$15.50 from C$16 at National Bank
CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

12/29/20 H.C. Wainwright
H.C. Wainwright reiterates $33 target on Cara after new drug filing
10/20/20 H.C. Wainwright
Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright
04/22/20 Cantor Fitzgerald
Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald
04/21/20 H.C. Wainwright
Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright
FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

07/29/20 DA Davidson
Comfort Systems USA price target raised to $45 from $32 at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/29/20 DA Davidson
Comfort Systems USA downgraded to Neutral from Buy at DA Davidson
04/20/20 Sidoti
Comfort Systems USA downgraded to Neutral from Buy at Sidoti
ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

03/15/21 H.C. Wainwright
Iterum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
12/24/20 H.C. Wainwright
Iterum CSO resignation 'somewhat troubling,' says H.C. Wainwright
06/16/20 H.C. Wainwright
Iterum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
06/02/20 RBC Capital
Iterum Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

08/10/20 ThinkEquity
Lantern Pharma initiated with a Buy at ThinkEquity
07/28/20 Colliers
Drug 'rescuer' Lantern Pharma started at Buy at Colliers
07/28/20 Colliers
Lantern Pharma initiated with a Buy at Colliers
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

03/31/21
Ocugen participates in a conference call with Cantor Fitzgerald
03/16/21 Roth Capital
Covaxin chances of U.S. approval now increased, says Roth Capital
03/04/21 Roth Capital
Ocugen price target raised to $10 from $9 at Roth Capital
03/04/21 Roth Capital
Roth boosts Ocugen target after partnered vaccine shows 'broad' efficacy
QURE uniQure
$33.77 /

-1.75 (-4.93%)

04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
03/29/21 H.C. Wainwright
uniQure probe 'important first step' toward lifting hold, says H.C. Wainwright
STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

01/20/21 Citi
Shattuck Labs price target raised to $75 from $36 at Citi
01/11/21 Evercore ISI
Shattuck Labs initiated with an Outperform at Evercore ISI
11/03/20 Needham
Shattuck Labs initiated with a Buy at Needham
11/03/20 Citi
Shattuck Labs initiated with a Buy at Citi
VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

02/18/21 Chardan
Chardan trims Viking Therapeutics target to $19 as COVID pushes out Voyage data
09/11/20 B. Riley
Viking Therapeutics price target raised to $15 from $12 at B. Riley FBR
09/01/20 BTIG
Viking Therapeutics price target raised to $12 from $9 at BTIG
08/30/20 Chardan
Viking Therapeutics price target raised to $20 from $15 at Chardan
ZEAL Zealand Pharma
$33.60 /

+1.27 (+3.93%)

VKTX Viking Therapeutics
$5.93 /

-0.23 (-3.73%)

TSHA Taysha Gene Therapies
$21.35 /

+1.49 (+7.50%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

STTK Shattuck Labs
$28.31 /

+1.365 (+5.07%)

RNA Avidity Biosciences
$22.12 /

-1.8 (-7.53%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

LTRN Lantern Pharma
$17.05 /

-0.13 (-0.76%)

LMAT LeMaitre
$51.38 /

+0.82 (+1.62%)

IVC Invacare
$8.23 /

-0.08 (-0.96%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CLSD Clearside Biomedical
$2.66 /

+0.12 (+4.72%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

  • 29
    Jan
  • 15
    Jan
  • 08
    Jan
  • 16
    Dec
  • 09
    Oct
  • 24
    Sep
  • 17
    Jul
  • 25
    Jun
  • 25
    Jun
  • 11
    Jun
  • 12
    Jun
  • 12
    Jun
OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

QURE uniQure
$33.77 /

-1.75 (-4.93%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

MEIP MEI Pharma
$3.43 /

+0.12 (+3.63%)

ITRM Iterum Therapeutics
$1.30 /

-0.305 (-19.00%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

GRCL Gracell
$13.52 /

-0.82 (-5.72%)

FIX Comfort Systems USA
$79.11 /

+1.925 (+2.49%)

CSTL Castle Biosciences
$69.44 /

-1.2 (-1.70%)

CARA Cara Therapeutics
$29.09 /

+1.645 (+5.99%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

PCVX Vaxcyte
$20.27 /

-0.49 (-2.36%)

OCGN Ocugen
$6.96 /

+0.045 (+0.65%)

IONS Ionis Pharmaceuticals
$42.32 /

-0.32 (-0.75%)

EVLO Evelo Biosciences
$10.03 /

+0.005 (+0.05%)

CYTK Cytokinetics
$24.17 /

+0.01 (+0.04%)

BSGM BioSig Technologies
$4.59 /

+0.12 (+2.68%)

AGI Alamos Gold
$8.37 /

+0.08 (+0.97%)

Hot Stocks
Synlogic presents data from SYNB1891 Phase 1 trial at AACR Annual Meeting » 17:41
04/11/21
04/11
17:41
04/11/21
17:41
SYBX

Synlogic

$3.34 /

-0.02 (-0.60%)

Synlogic presented data…

Synlogic presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research annual meeting. SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphoma. SYNB1891 is composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP, a stimulator of the STING pathway. This mechanism can play a critical role in the initiation of an anti-tumor immune response via activation of APCs and presentation of tumor antigens. Findings from the monotherapy cohorts include: SYNB1891 is safe and well-tolerated as an intratumoral injection in a heterogenous population; No dose limiting toxicities or SYNB1891-related infections; Dose levels through 1e7 live cells demonstrate target engagement as assessed by dose-dependent increases in serum cytokines, upregulation of ISGs and presence of tumor infiltrating lymphocytes; Evidence of durable stable disease was seen in 2 patients and was associated with upregulation genes tied to immune activation and increased intratumoral lymphocytes. These data support continued dose escalation in the monotherapy and combination arms. The combination arm of the study combines escalating dose levels of SYNB1891 with a fixed dose of a PD-L1 checkpoint inhibitor antibody to establish a recommended Phase 2 dose for the combination regimen. Data from both arms will continue to be reported over the course of 2021, with mature combination therapy data expected by the end of the year.

ShowHide Related Items >><<
SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

SYBX Synlogic
$3.34 /

-0.02 (-0.60%)

Conference/Events
Synlogic management to meet virtually with Piper Sandler » 05:55
04/09/21
04/09
05:55
04/09/21
05:55
SYBX

Synlogic

$3.36 /

+0.06 (+1.82%)

Virtual Meeting to be…

Virtual Meeting to be held April 8-9 hosted by Piper Sandler.

ShowHide Related Items >><<
SYBX Synlogic
$3.36 /

+0.06 (+1.82%)

SYBX Synlogic
$3.36 /

+0.06 (+1.82%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.36 /

+0.06 (+1.82%)

SYBX Synlogic
$3.36 /

+0.06 (+1.82%)

Conference/Events
Synlogic management to meet virtually with Piper Sandler » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
SYBX

Synlogic

$3.34 /

-0.21 (-5.92%)

Virtual Meeting to be…

Virtual Meeting to be held April 8-9 hosted by Piper Sandler.

ShowHide Related Items >><<
SYBX Synlogic
$3.34 /

-0.21 (-5.92%)

SYBX Synlogic
$3.34 /

-0.21 (-5.92%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.34 /

-0.21 (-5.92%)

SYBX Synlogic
$3.34 /

-0.21 (-5.92%)

Over a month ago
Conference/Events
Synlogic management to meet virtually with Piper Sandler » 10:54
04/05/21
04/05
10:54
04/05/21
10:54
SYBX

Synlogic

$3.65 /

+0.04 (+1.11%)

Virtual Meeting to be…

Virtual Meeting to be held April 8-9 hosted by Piper Sandler.

ShowHide Related Items >><<
SYBX Synlogic
$3.65 /

+0.04 (+1.11%)

SYBX Synlogic
$3.65 /

+0.04 (+1.11%)

03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
SYBX Synlogic
$3.65 /

+0.04 (+1.11%)

SYBX Synlogic
$3.65 /

+0.04 (+1.11%)

Recommendations
Synlogic price target raised to $15 from $10 at SVB Leerink » 13:39
03/25/21
03/25
13:39
03/25/21
13:39
SYBX

Synlogic

$3.85 /

+ (+0.00%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz raised the firm's price target on Synlogic to $15 from $10 and keeps an Outperform rating on the shares. The analyst argues that "promising" Phase 1 data in healthy volunteers for SYNB8802 increases the likelihood of Synlogic demonstrating meaningful efficacy in patients with enteric hyperoxaluria in the second half of the year. Schwartz acknowledges, however, that the stock seems to be reacting negatively to the -10% reduction of UOx from baseline in HVs treated with SYNB8802 that is more modest than the +29% increase in UOx from baseline in HVs on placebo. He believes the reaction is an "oversimplification of the data" and presents a buying opportunity for investors since the analyst thinks the "insightful" Phase 1 data in HVs de-risks the platform and suggests that the results in enteric HOX patients expected in the second half of the year could be attractive.

ShowHide Related Items >><<
SYBX Synlogic
$3.85 /

+ (+0.00%)

SYBX Synlogic
$3.85 /

+ (+0.00%)

03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
SYBX Synlogic
$3.85 /

+ (+0.00%)

SYBX Synlogic
$3.85 /

+ (+0.00%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
03/25/21
03/25
08:55
03/25/21
08:55
LITE

Lumentum

$79.04 /

-3.45 (-4.18%)

, ENOB

Enochian Biosciences

$3.51 /

-0.25 (-6.65%)

, SYBX

Synlogic

$3.84 /

-0.26 (-6.34%)

, AMWL

Amwell

$18.59 /

-0.41 (-2.16%)

, DRI

Darden

$133.77 /

-2.98 (-2.18%)

, MOV

Movado

$21.62 /

-0.69 (-3.09%)

, RH

RH

$486.00 /

-20.61 (-4.07%)

, IIVI

II-VI

$67.32 /

+1.39 (+2.11%)

, RAD

Rite Aid

$23.33 /

-0.42 (-1.77%)

, EVFM

Evofem

$2.33 /

-0.245 (-9.53%)

, COHR

Coherent

$257.00 /

-2 (-0.77%)

Check out this morning's…

ShowHide Related Items >><<
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

03/18/21
Fly Intel: Top five analyst downgrades
03/18/21 Susquehanna
Lumentum bid for Coherent reaching risk tolerance limits, says Susquehanna
03/18/21 Rosenblatt
Lumentum downgraded to Neutral on Apple headwinds at Rosenblatt
03/18/21 Rosenblatt
Lumentum downgraded to Neutral from Buy at Rosenblatt
ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
AMWL Amwell
$18.59 /

-0.41 (-2.16%)

03/25/21 Cowen
Amwell price target lowered to $35 from $41 at Cowen
03/25/21 Piper Sandler
Amwell price target lowered to $30 from $45 at Piper Sandler
03/23/21 Piper Sandler
Piper remains buyer of telehealth companies despite Amazon competition
03/17/21 Stephens
Amazon news latest sign of rising telehealth competition, says Stephens
DRI Darden
$133.77 /

-2.98 (-2.18%)

03/23/21 RBC Capital
Darden price target raised to $151 from $138 at RBC Capital
03/22/21 Raymond James
Darden price target raised to $155 from $137.50 at Raymond James
03/19/21 Barclays
Darden price target raised to $145 from $131 at Barclays
03/18/21 Wells Fargo
Darden price target raised to $160 from $140 at Wells Fargo
MOV Movado
$21.62 /

-0.69 (-3.09%)

RH RH
$486.00 /

-20.61 (-4.07%)

03/25/21 Wedbush
RH price target raised to $550 from $520 at Wedbush
03/25/21 Wells Fargo
RH price target raised to $575 from $525 at Wells Fargo
03/25/21 Loop Capital
RH price target raised to $600 from $520 at Loop Capital
03/25/21 Cowen
RH price target raised to $600 from $570 at Cowen
IIVI II-VI
$67.32 /

+1.39 (+2.11%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
12/18/20 Deutsche Bank
Rite Aid price target raised to $17 from $9 at Deutsche Bank
11/17/20 Oppenheimer
Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
COHR Coherent
$257.00 /

-2 (-0.77%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

COHR Coherent
$257.00 /

-2 (-0.77%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

  • 25
    Mar
  • 15
    Jan
  • 17
    Sep
  • 02
    Jul
  • 03
    Jun
  • 21
    Apr
LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.